Literature DB >> 28795336

The ever-evolving role of pathologists in the management of breast cancer with neoadjuvant treatment: recommendations based on the Spanish clinical experience.

O Burgués1, Mª Á López-García2, B Pérez-Míes3, P Santiago4, B Vieites2, J F García5, V Peg6.   

Abstract

PURPOSE: To compare the current international standards for neoadjuvant systemic therapy (NAST) protocols, and establish consensus recommendations by Spanish breast pathologists; and to look into the Spanish reality of defining pathological complete response in daily practice.
MATERIALS AND METHODS: A modified Delphi technique was used to gain consensus among a panel of 46 experts with regard to important issues about NAST specimens, with the objective of standardize handling and analysis of these breast cancer specimens. In addition, a survey was conducted among 174 pathologists to explore the Spanish reality of post-NAST breast cancer specimens handling.
RESULTS: Our survey shows that pathologists in Spain follow the same guidelines as their international colleagues and face the same problems and controversies. Among the experts, 94.1% agreed on the recommendation for a pre-treatment evaluation with a core needle biopsy, and 100% of experts agreed on the need of having properly indicated information for the post-NAST surgical specimens. However, only 82.7% of them receive properly labelled specimens and even less receive specimens where markers are identified and the degree of clinical/radiological response is mentioned. Among participants 59.9% were familiar with the residual cancer burden system for post-NAST response quantification, but only 16.1% used it regularly.
CONCLUSIONS: Active participation on breast cancer multidisciplinary teams, optimal usage of core needle biopsy for timely and standardized procedures for the diagnostic analysis, and accurate diagnosis of pathological complete response and complete evaluation of the response to NAST need to become the standard practice when handling breast cancer specimens in Spain.

Entities:  

Keywords:  Breast cancer; Neoadjuvant treatment; Pathology; Recommendation

Mesh:

Year:  2017        PMID: 28795336     DOI: 10.1007/s12094-017-1725-z

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  40 in total

1.  Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy.

Authors:  A Sheri; I E Smith; S R Johnston; R A'Hern; A Nerurkar; R L Jones; M Hills; S Detre; S E Pinder; W F Symmans; M Dowsett
Journal:  Ann Oncol       Date:  2014-10-30       Impact factor: 32.976

2.  Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer.

Authors:  Véronique Diéras; Pierre Fumoleau; Gilles Romieu; Michèle Tubiana-Hulin; Moïse Namer; Louis Mauriac; Jean-Paul Guastalla; Eric Pujade-Lauraine; Pierre Kerbrat; Philippe Maillart; Frédérique Pénault-Llorca; Marc Buyse; Pierre Pouillart
Journal:  J Clin Oncol       Date:  2004-12-15       Impact factor: 44.544

3.  The Perfect Pathology Report After Neoadjuvant Therapy.

Authors:  Caterina Marchiò; Francesca Maletta; Laura Annaratone; Anna Sapino
Journal:  J Natl Cancer Inst Monogr       Date:  2015-05

Review 4.  Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies.

Authors:  Ivan R Diamond; Robert C Grant; Brian M Feldman; Paul B Pencharz; Simon C Ling; Aideen M Moore; Paul W Wales
Journal:  J Clin Epidemiol       Date:  2014-04       Impact factor: 6.437

5.  Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.

Authors:  W Fraser Symmans; Florentia Peintinger; Christos Hatzis; Radhika Rajan; Henry Kuerer; Vicente Valero; Lina Assad; Anna Poniecka; Bryan Hennessy; Marjorie Green; Aman U Buzdar; S Eva Singletary; Gabriel N Hortobagyi; Lajos Pusztai
Journal:  J Clin Oncol       Date:  2007-09-04       Impact factor: 44.544

6.  Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.

Authors:  Judy C Boughey; Vera J Suman; Elizabeth A Mittendorf; Gretchen M Ahrendt; Lee G Wilke; Bret Taback; A Marilyn Leitch; Henry M Kuerer; Monet Bowling; Teresa S Flippo-Morton; David R Byrd; David W Ollila; Thomas B Julian; Sarah A McLaughlin; Linda McCall; W Fraser Symmans; Huong T Le-Petross; Bruce G Haffty; Thomas A Buchholz; Heidi Nelson; Kelly K Hunt
Journal:  JAMA       Date:  2013-10-09       Impact factor: 56.272

7.  Ki67 measured after neoadjuvant chemotherapy for primary breast cancer.

Authors:  Gunter von Minckwitz; Wolfgang D Schmitt; Sibylle Loibl; Berit M Müller; Jens U Blohmer; Bruno V Sinn; Holger Eidtmann; Wolfgang Eiermann; Bernd Gerber; Hans Tesch; Jörn Hilfrich; Jens Huober; Tanja Fehm; Jana Barinoff; Thomas Rüdiger; Erhard Erbstoesser; Peter A Fasching; Thomas Karn; Volkmar Müller; Christian Jackisch; Carsten Denkert
Journal:  Clin Cancer Res       Date:  2013-06-27       Impact factor: 12.531

8.  Standardized synoptic cancer pathology reporting: a population-based approach.

Authors:  John R Srigley; Tom McGowan; Andrea Maclean; Marilyn Raby; Jillian Ross; Sarah Kramer; Carol Sawka
Journal:  J Surg Oncol       Date:  2009-06-15       Impact factor: 3.454

9.  A central review of histopathology reports after breast cancer neoadjuvant chemotherapy in the neo-tango trial.

Authors:  E Provenzano; A-L Vallier; R Champ; K Walland; S Bowden; A Grier; N Fenwick; J Abraham; M Iddawela; C Caldas; L Hiller; J Dunn; H M Earl
Journal:  Br J Cancer       Date:  2013-01-08       Impact factor: 7.640

10.  Standardised method for reporting exercise programmes: protocol for a modified Delphi study.

Authors:  Susan C Slade; Clermont E Dionne; Martin Underwood; Rachelle Buchbinder
Journal:  BMJ Open       Date:  2014-12-30       Impact factor: 2.692

View more
  2 in total

1.  Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement.

Authors:  Ramon Colomer; Cristina Saura; Pedro Sánchez-Rovira; Tomás Pascual; Isabel T Rubio; Octavio Burgués; Lourdes Marcos; César A Rodríguez; Miguel Martín; Ana Lluch
Journal:  Oncologist       Date:  2019-02-01

Review 2.  Developing consensus in Histopathology: the role of the Delphi method.

Authors:  Dilek Taze; Collette Hartley; Ann W Morgan; Aruna Chakrabarty; Sarah L Mackie; Kathryn J Griffin
Journal:  Histopathology       Date:  2022-04-24       Impact factor: 7.778

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.